The core activity of Perseo Pharma AG is the development of enzyme replacement therapies for the treatment of metabolic diseases, in particular for rare diseases such as exocrine pancreatic insufficiency, congenital sucrase-isomaltase deficiency and maple syrup urine disease. The company develops innovative therapies based on the enzzen platform technology and focuses on the clinical development of active ingredients for the treatment of these diseases.
AI-generated
Offering
Products & services
Industry:Research & Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of oral enzyme therapies for digestive conditions, based on a proprietary nanotechnology platform with nano-shield and muco-adhesive coating.
Nanotechnology Platform for Oral Enzyme Therapies
Proprietary platform that protects enzymes in silica nanoparticles and an organo-silica layer, prolonging their residence time in the small intestine and maintaining activity.
Development of Therapies for Digestive Diseases
Research and development of therapies for exocrine pancreatic insufficiency, carbohydrate malabsorption, PKU, CSID and MSUD.
Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases
Research on systemic enzyme replacement therapies for lysosomal storage diseases as part of the second development wave.
Partnerships for the Co-Development of Innovative Therapies
Cooperations for the co-development of innovative therapies in the areas of metabolic therapies, onco-metabolism and systemic enzyme replacement therapies.